BridgeBio Pharma (BBIO) Receivables - Other (2019 - 2024)

BridgeBio Pharma has reported Receivables - Other for 6 years, with the latest figure at $200000.0 in Q3 2024.

• Quarterly Receivables - Other fell 94.12% year-over-year to $200000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $200000.0 (down 94.12% YoY) and the FY2023 annual result came in at $900000.0, down 94.64% from the prior year.
• Receivables - Other held at $200000.0 in Q3 2024 per BBIO's latest filing, from $200000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $100.4 million in Q1 2024 and troughed at $200000.0 in Q2 2024.
• A 5-year average of $14.0 million and a median of $6.4 million in 2021 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2024: Receivables - Other soared 6956.28% in 2022, then tumbled 96.92% in 2024.
• Over 5 years, Receivables - Other stood at $8.0 million in 2020, then decreased by 21.25% to $6.3 million in 2021, then surged by 166.67% to $16.8 million in 2022, then sank by 94.64% to $900000.0 in 2023, then tumbled by 77.78% to $200000.0 in 2024.
• According to Business Quant data, Receivables - Other over the past three periods registered $200000.0, $200000.0, and $100.4 million for Q3 2024, Q2 2024, and Q1 2024 respectively.